Avalo Therapeutics Inc AVTX:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
Last | 04/18/24 EDT
12.01quote price arrow down-1.61 (-11.82%)
Volume
102,300
52 week range
3.95 - 1,130.40
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close12.01
  • 52 Week High1,130.40
  • 52 Week High Date06/23/23
  • 52 Week Low3.95
  • 52 Week Low Date01/17/24

Key Stats

  • Market Cap12.42M
  • Shares Out1.03M
  • 10 Day Average Volume0.24M
  • Dividend-
  • Dividend Yield-
  • Beta1.27
  • YTD % Change31.98

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close12.01
  • 52 Week High1,130.40
  • 52 Week High Date06/23/23
  • 52 Week Low3.95
  • 52 Week Low Date01/17/24
  • Market Cap12.42M
  • Shares Out1.03M
  • 10 Day Average Volume0.24M
  • Dividend-
  • Dividend Yield-
  • Beta1.27
  • YTD % Change31.98

RATIOS/PROFITABILITY

  • EPS (TTM)-381.66
  • P/E (TTM)-0.03
  • Fwd P/E (NTM)-1.84
  • EBITDA (TTM)-23.285M
  • ROE (TTM)-524.01%
  • Revenue (TTM)1.925M
  • Gross Margin (TTM)33.25%
  • Net Margin (TTM)-1,638.65%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/02/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Avalo Therapeutics Inc

 

Profile

MORE
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (AVTX-002) (anti-LIGHT monoclonal antibody (mAb)) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity....
Garry Neil M.D.
Chairman of the Board, President, Chief Executive Officer
Christopher Sullivan CPA
Chief Financial Officer
Address
540 Gaither Rd Ste 400
Rockville, MD
20850-6713
United States

Top Peers

SYMBOLLASTCHG%CHG
SEEL
Seelos Therapeutics Inc
0.338+0.006+1.8072%
TLPH
Talphera Inc
1.04+0.03+2.97%
KALA
KALA BIO Inc
6.81-0.03-0.41%
TRVN
Trevena Inc
0.366-0.036-8.9552%
GTBP
GT Biopharma Inc
3.80-0.17-4.28%